Last updated: September 18, 2026
Tolectin DS is the former brand name for tolmetin sodium 600 mg, a nonsteroidal anti-inflammatory drug used for osteoarthritis and rheumatoid arthritis. Its commercial trajectory is that of a mature, largely genericized NSAID rather than an active branded-growth product. The original U.S. regulatory exclusivity period expired decades ago, no meaningful biosimilar issue exists, and publicly reported revenue for Tolectin DS is not separately disclosed. Current value is concentrated in generic supply, residual prescribing, manufacturing know-how, and any surviving country-specific registrations.
What is Tolectin DS and who marketed it?
Tolectin DS contains tolmetin sodium, an orally administered NSAID. The "DS" designation generally refers to the 600 mg strength, while lower-strength tolmetin products were also marketed historically.
| Product attribute |
Information |
| Brand |
Tolectin DS |
| Active ingredient |
Tolmetin sodium |
| Drug class |
Nonsteroidal anti-inflammatory drug |
| Primary indications |
Rheumatoid arthritis and osteoarthritis |
| Dosage form |
Immediate-release oral tablet |
| Key strength |
600 mg |
| U.S. regulatory history |
Approved in the 1970s |
| Current commercial position |
Legacy brand with generic substitution |
| Biologic status |
Small molecule; biosimilar pathway does not apply |
| Revenue disclosure |
No separate public Tolectin DS revenue reporting identified |
The product was associated historically with McNeil Pharmaceutical and later corporate pharmaceutical portfolios. Brand ownership and distribution arrangements changed over time, but the commercial identity of Tolectin DS did not develop into a current high-value branded franchise.
FDA labeling describes tolmetin sodium as an NSAID indicated for the signs and symptoms of rheumatoid arthritis and osteoarthritis. The labeling also identifies established NSAID risks, including gastrointestinal bleeding, cardiovascular thrombotic events, renal toxicity, and hypersensitivity reactions (U.S. Food and Drug Administration [FDA], n.d.-a).
When did Tolectin DS lose exclusivity?
Tolectin DS lost practical market exclusivity many years ago. Its original approval predates the modern Hatch-Waxman patent-certification framework, and generic tolmetin sodium products have been available for an extended period.
The relevant commercial conclusion is straightforward:
- FDA approval occurred in the 1970s.
- Any original composition-of-matter or basic product exclusivity expired decades ago.
- Generic tolmetin sodium became the principal competitive product.
- Current value is not protected by a live, commercially meaningful U.S. brand moat.
A precise original patent-expiration date is not a reliable indicator of current value because the brand has passed through multiple ownership and marketing periods, while the active ingredient has long been treated as an established generic drug.
What is the FDA regulatory status of Tolectin DS?
The FDA regulatory status is that of an old, approved small-molecule NSAID and its generic equivalents. The FDA-approved labeling remains relevant for safety, dosage, contraindications, and warnings, but the regulatory record does not indicate a current innovative-product lifecycle program.
FDA milestones
| Milestone |
Approximate period or status |
| Initial U.S. approval |
1970s |
| Brand commercialization |
Historical |
| Generic availability |
Established for many years |
| Current regulatory pathway |
ANDA-based generic supply for tolmetin sodium |
| Current innovation exclusivity |
None known |
| Pediatric exclusivity |
None known for the legacy product |
| Orphan-drug exclusivity |
Not applicable |
| REMS |
No major product-specific REMS identified |
| Biosimilar pathway |
Not applicable |
The FDA Orange Book is the principal source for approved drug products, therapeutic-equivalence evaluations, and patent listings. For an old product such as Tolectin DS, the key commercial inquiry is whether the branded NDA remains actively marketed and whether any listed patents remain unexpired. The Orange Book does not create exclusivity by itself; it records patent and exclusivity information associated with approved drug applications (FDA, n.d.-b).
What patents protect Tolectin DS?
No current, commercially significant U.S. patent estate for Tolectin DS has been identified in the public regulatory record. The product is not generally understood to have an active Orange Book patent barrier that would delay generic entry.
Patent categories relevant to tolmetin sodium
| Patent category |
Current commercial relevance |
| Active ingredient patent |
Expired or no longer commercially relevant |
| Salt-form patent |
No material current barrier identified |
| Immediate-release tablet patent |
No material current barrier identified |
| 600 mg strength patent |
No material current barrier identified |
| Method-of-use patent |
No material current barrier identified |
| Manufacturing-process patent |
Potentially relevant only if privately held and unexpired |
| Packaging or distribution patent |
No known market-level barrier |
| Orange Book-listed patent |
No current blocking estate identified |
The absence of a known active patent estate does not mean that every historical patent has been located or that no process patent exists in any jurisdiction. It does mean that patent rights are not the principal determinant of U.S. market access for tolmetin sodium.
What is the Orange Book status of Tolectin DS?
Tolectin DS should be analyzed separately from generic tolmetin sodium tablets. A legacy brand may remain in historical FDA records even when commercial distribution has ceased or when the product is no longer a meaningful source of prescriptions.
The principal Orange Book questions are:
- Whether the original Tolectin NDA is listed as currently marketed.
- Whether tolmetin sodium ANDAs remain approved and therapeutically equivalent.
- Whether any patents are listed for the reference product.
- Whether the reference product has a current, commercially active label.
FDA Orange Book records distinguish approval status from actual commercial availability. A product can remain in regulatory databases after commercial discontinuation. That distinction is material for valuation and generic-entry analysis.
How many patents cover Tolectin DS?
The current practical answer is zero known blocking U.S. patents with meaningful market impact.
Historical patent coverage may have included patents relating to tolmetin, salt forms, dosage strengths, formulations, or manufacturing. Those rights are unlikely to constrain current generic supply because the active ingredient and conventional oral dosage form have been commercially available for decades.
Patent risk is therefore low for ordinary U.S. tolmetin sodium tablets. The more relevant risks are regulatory compliance, product quality, supply continuity, and demand erosion.
What formulations are protected by Tolectin DS?
Tolectin DS is an immediate-release oral tablet, not a complex drug-delivery system. The formulation does not appear to depend on a difficult-to-replicate extended-release matrix, transdermal system, injectable depot, inhalation device, or biologic manufacturing platform.
Formulation and manufacturing profile
The commercial product has a relatively low technical barrier because:
- The active ingredient is a conventional small molecule.
- The dosage form is an oral tablet.
- The 600 mg strength is not dependent on a novel delivery device.
- Generic manufacturers can use established solid-dose manufacturing infrastructure.
- Bioequivalence requirements are materially less complex than for biologics or complex injectables.
Manufacturing barriers may still arise from active pharmaceutical ingredient sourcing, quality-system requirements, validation, stability data, and low-volume economics. These are execution barriers rather than durable intellectual-property barriers.
Which companies are challenging Tolectin DS?
The competitive challenge is principally generic substitution, not Paragraph IV litigation.
Tolmetin sodium products have historically been marketed by multiple generic manufacturers and labelers. The number of active suppliers can change because older low-volume products are frequently discontinued, transferred, or maintained by a limited number of contract manufacturers.
Paragraph IV and litigation position
No major current Paragraph IV campaign or high-value patent litigation involving Tolectin DS has been identified. That outcome is consistent with the product's age and lack of a meaningful active patent estate.
Paragraph IV litigation is generally relevant when a generic applicant challenges an unexpired Orange Book patent. For tolmetin sodium, the commercial pathway is more likely to involve ordinary ANDA approval, therapeutic equivalence, supply decisions, and market entry without a prolonged patent dispute.
What is the generic entry risk for Tolectin DS?
Generic entry risk is effectively realized rather than prospective. Generic competition already defines the product's economics.
| Risk area |
Assessment |
| New generic entry |
High, although market size may limit participation |
| Patent-based delay |
Low |
| Regulatory exclusivity delay |
Low |
| Brand retention |
Low |
| Price erosion |
High |
| Supply interruption |
Moderate, depending on supplier count |
| Product substitution |
High |
| Biosimilar competition |
Not applicable |
| Litigation exposure |
Low |
The main commercial risk is not a sudden generic launch. It is continuing erosion of volume and price as prescribers and pharmacies use lower-cost generic tolmetin or substitute other NSAIDs.
How does Tolectin DS compare with competing NSAIDs?
Tolectin DS competes with a broad group of established NSAIDs, including naproxen, ibuprofen, diclofenac, indomethacin, meloxicam, and celecoxib.
| Product |
Market position relative to tolmetin |
| Ibuprofen |
Broad over-the-counter and prescription competition |
| Naproxen |
Strong chronic-pain and arthritis competitor |
| Diclofenac |
Widely used in oral and topical formulations |
| Meloxicam |
Common once-daily prescription alternative |
| Celecoxib |
Branded and generic COX-2 selective competitor |
| Indomethacin |
Niche prescription NSAID with different use patterns |
| Tolmetin |
Mature, lower-volume generic NSAID |
Tolmetin's disadvantages include limited brand investment, strong substitution pressure, and competition from agents with greater prescribing familiarity or more convenient dosing. Its possible advantages are historical clinical familiarity and availability in a 600 mg tablet, but these characteristics do not create a defensible premium market.
What is the financial trajectory of Tolectin DS?
The financial trajectory is consistent with a mature, declining, low-revenue pharmaceutical product.
Revenue exposure
No major pharmaceutical company currently reports Tolectin DS revenue as a separate material operating segment. Public-company disclosures generally aggregate mature generic products into broader categories, making product-level sales difficult to isolate.
The likely trajectory is:
| Period |
Financial profile |
| Initial launch period |
Branded prescription revenue with limited competition |
| Post-exclusivity period |
Volume growth constrained by generic entry |
| Mature generic period |
Price compression and fragmented supply |
| Current period |
Low-value, residual or generic-only economics |
| Forward outlook |
Stable-to-declining demand with possible supply volatility |
Revenue exposure is likely immaterial for a diversified pharmaceutical company. It can still matter for a small generic manufacturer if the product has limited competition, a hospital or government contract, or a temporary supply shortage. That value would arise from market structure, not patent protection.
What licensing deals involve Tolectin DS?
No major current licensing or partnership transaction centered on Tolectin DS has been identified. Historical brand transfers may have occurred as part of broader pharmaceutical portfolio transactions, but Tolectin DS has not been a visible driver of modern licensing activity.
The absence of licensing activity reflects three factors:
- The product has no apparent platform technology.
- The ingredient is widely known and genericized.
- Commercial upside is limited without a new formulation, indication, or geographic opportunity.
A transaction involving tolmetin sodium would more likely concern a generic product portfolio, manufacturing rights, or regional registration than a standalone branded asset.
What manufacturing and geographic barriers affect tolmetin sodium?
U.S. patent barriers are low, but geographic and manufacturing conditions can still affect availability.
Geographic coverage
Tolmetin has had international regulatory and commercial exposure, but product names, strengths, marketing rights, and current availability vary by country. A product may be listed in one jurisdiction while absent from another because of:
- National registration status.
- Local commercial demand.
- Reimbursement rules.
- Pharmacovigilance obligations.
- Manufacturing economics.
- Local patent or data-exclusivity rules.
- Distributor strategy.
The U.S. generic market is the most relevant reference point for patent analysis. Foreign rights require country-specific searches and cannot be inferred from U.S. Orange Book data.
Manufacturing barriers
Potential barriers include:
- Limited API suppliers.
- Low batch volumes.
- Expensive regulatory maintenance for an old product.
- Facility inspection or compliance issues.
- Product transfer delays.
- Stability or dissolution failures.
- Discontinuation by one or more generic manufacturers.
These issues can create temporary shortages or price increases even without patent protection. They do not support a durable premium unless supply remains concentrated and demand persists.
What patent litigation affects Tolectin DS?
No material current patent litigation involving Tolectin DS has been identified. The product's legal risk is more likely to arise from ordinary pharmaceutical issues, including:
- Product-liability claims.
- Labeling disputes.
- Manufacturing-quality investigations.
- Supply or distribution contracts.
- False-claims or promotional matters involving historical marketing.
The absence of high-value patent litigation reduces legal overhang but also confirms that the asset has little remaining exclusivity value.
What are the likely generic launch scenarios?
Because generic competition is already established, the relevant scenarios concern supply and market concentration.
Base case
Multiple generic sources continue supplying tolmetin sodium at low prices. Brand Tolectin DS remains commercially insignificant.
Upside case for a generic manufacturer
A supplier exits, competitors experience manufacturing problems, and the remaining approved manufacturer captures temporary volume and pricing power. This is a supply-concentration opportunity, not a patent opportunity.
Downside case
Prescribing continues to shift toward naproxen, meloxicam, celecoxib, diclofenac, or over-the-counter ibuprofen. Low demand leads additional suppliers to discontinue the product.
Key Takeaways
- Tolectin DS is the legacy brand for tolmetin sodium 600 mg.
- It is a mature small-molecule NSAID with no biosimilar issue.
- U.S. market exclusivity expired decades ago.
- No current blocking patent estate or major Paragraph IV dispute is identified.
- Generic substitution, not patent litigation, drives market dynamics.
- Product-level revenue is not separately disclosed and is likely immaterial to major pharmaceutical companies.
- Commercial value depends on residual demand, supplier concentration, manufacturing reliability, and regional registrations.
- The most plausible financial trajectory is low and declining brand value with occasional generic supply opportunities.
- Any investment thesis should focus on generic portfolio economics rather than Tolectin DS as an innovative branded asset.
FAQs
Is Tolectin DS still available in the United States?
The historical brand may no longer have meaningful commercial distribution, but tolmetin sodium tablets can remain available through generic or legacy-label channels. FDA database status and pharmacy availability are separate questions.
Is tolmetin sodium a controlled substance?
No. Tolmetin sodium is an NSAID and is not scheduled as a controlled substance under the U.S. Controlled Substances Act.
Does Tolectin DS have a new-drug exclusivity period?
No current exclusivity period is associated with the legacy product. Any original exclusivity expired many years ago.
Can a company obtain an Orange Book patent for a new tolmetin formulation?
A genuinely new, patentable formulation or delivery system could potentially support patent protection, subject to patentability and FDA requirements. A conventional tolmetin sodium tablet would face a much weaker basis for new exclusivity.
Is tolmetin sodium commercially attractive for generic manufacturers?
It may be attractive when supplier competition is limited or a shortage creates temporary pricing power. In a normal multi-supplier market, the product is a low-margin, mature generic with limited growth potential.
References
-
U.S. Food and Drug Administration. (n.d.-a). Tolmetin sodium prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. National Library of Medicine. (n.d.). Tolmetin. PubChem. https://pubchem.ncbi.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-d). Generic drugs. https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs
